SeaStar Medical (ICU) news
Recent news
FDA grants Seastar medical breakthrough device designation for its SCD therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition
SeaStar Medical Holding Corp. (Nasdaq: ICU) has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. This…
AInvest Wire · 7d agoSeastar Medical announces chief medical officer, Kevin Chung, M.D., to present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Seastar Medical has announced that Kevin Chung, M.D., its chief medical officer, will present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026. The event, which focuses on advancements in pediatric extracorporeal therapies, is expected to draw medical professionals,…
AInvest Wire · Sep 29, 2026ImportantSeaStar Medical offers 6.3M shares; its stock down ~2% in the session
AInvest Wire · Jan 30, 2024ImportantSeaStar Medical jumps 26% premarket after FDA issued approvable letter for the Co.'s selective cytopheretic device for pediatric patients
AInvest Wire · Oct 30, 2023ImportantSeaStar medical shares surge 55% on FDA breakthrough designation
AInvest Wire · Oct 18, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.